Human rhinoviruses (HRVs) belong to the family Picornaviridae of small, icosahedral, non-enveloped viruses containing 7.5 kb long positive-stranded RNA genomes. There are over 300 serologically distinct human rhinoviruses which are divided to A, B, and C types. Infected patients exhibit diseases ranging from mild upper respiratory tract common colds to severe lower respiratory tract bouts of bronchiolitis, wheeze, and asthma exacerbation. Viruses belonging to human rhinoviruses type C are more genetically diverse than viruses of A and B types and are more prone to stimulate asthma reactivity or more virulent. There are no specific treatments for HRV-C infections. Viruses of the C type use cadherin-related family member 3 protein as receptor for their cell entry. This receptor is not expressed in undifferentiated immortalized cells commonly used for propagation of viruses in tissue cultures, which complicates cultivation of HRV-Cs. In this work we plan to use recombinant vaccinia virus for delivery and expression of HRV-C3 in Hela cells. The recombinant vaccinia virus will contain HRV-C3 genome sequence and gpt/fluorescence selection marker integrated into vaccinia thymidine kinase locus. HRV-C3 will be expressed under the control of vaccinia early or early/late promoter combined with tetracycline-dependent operators. HRV-C3 is tagged with HA-tag or BoBS aptamer for further detection. Expressed and purified HRV-C3 will be used for structure determination by cryo-electron microscopy.